Stocks-VRDN-Viridian Therapeutics Inc

VRDN Viridian Therapeutics Inc

25.74 0.24 (0.94%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Invest

Performance

-6.83% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
1.1B
Day’s Range
24.97
-
25.77
52W Range
9.42
-
38.87
Volume (3M)
565.59K
Price-Earnings Ratio
-6.38
Revenue
1.77M

Viridian Therapeutics Inc Latest News

View All
Pinned Post
eToro Team
📰 EXTRA EXTRA…New charts arrived on eToro! Today we would like to give an official welcome to our new charts, in partnership with TradingView, one of the market leaders in charting and analysis tools. Yes, we know! You have already noticed the change but now we want to share with you what this complete... Show More
Like CommentShare
Show more comments2 of 63
2 replies
null
.
Top Discussions
MarketUpdates
Edited
$VRDN (Viridian Therapeutics Inc) Q1 2023 earnings report is expected to be released
11
MAY
REPORTS
Viridian Therapeutics Inc Q1 2023 earnings report is expected to be released before market open
Notify me
VRDN
VRDN
Viridian Therapeutics Inc
25.74
0.24
(0.94%)
Trade
MarketUpdates
$VRDN (Viridian Therapeutics Inc) Q1 2023 earnings report is expected to be released
MarketUpdates
$VRDN (Viridian Therapeutics Inc) Q1 2023 earnings report is expected to be released
4headtrade
Edited
Like CommentShare
null
.
4headtrade
📢Upcoming Earnings this week📢📈 📅Week beginning 6/03/2023 📅 📅Monday 6th📅: 📈Before Open📈: $CIEN (Ciena Corp) $AZUL (Azul SA-ADR) $RIDE (Lordstown Motors Corp) 📈After Close📈: $NTNX ( Nutanix Inc A) $TCOM.CH (Trip.com Group Ltd-ADR) DOMO AVAV CARA GWRE BBVA.MC 📅Tuesday 7th📅: 📈Before... Show More
Like CommentShare
null
.

About Viridian Therapeutics Inc

Viridian Therapeutics, Inc. is a biotechnology company that develops treatments for serious diseases, including thyroid eye disease and rare diseases that are underserved by current therapies. Founded in 2006, Viridian Therapeutics has its headquarters in Boulder, Colorado. Previously known as Miragen Therapeutics, Inc., the company changed its name in January 2021 to Viridian Therapeutics, Inc. The most advanced program that Viridian has underway is VRDN-001, which is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody developed to treat thyroid eye disease, a debilitating auto-immune disease with poor treatment options. The company also has a VRDN-002 program focused on the development of a biosuperior IGF-1R antibody. VRDN-002 is a second-generation product candidate designed for subcutaneous administration. Additionally, Viridian Therapeutics has VRDN-004 and VRDN-005 programs in the pipeline. Available on the NASDAQ, Viridian Therapeutics, Inc. stock is listed under the ticker VRDN. The company's IPO raised approximately $97.7m before expenses in September 2021. Viridian has stated that it intends to use the proceeds to advance the development of VRDN-001 and VRDN-002, in addition to funding preclinical development of its VRDN-004 and VRDN-005 programs and for general corporate purposes and working capital. Keep an eye on the price movements of VRDN stock by adding it to your eToro watchlist.
50
Employees
Waltham, Massachusetts, US
HQ
2006
Founded
Scott D. Myers, MBA
CEO
Show More

Upcoming Earnings

11
MAY
REPORTS
Viridian Therapeutics Inc Q1 2023 earnings report is expected to be released before market open

Analyst Forecast

Consensus
Moderate Buy
Price Target
42.50

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
37
Very Low
Industry 
Avg. 47 
34
Environment
35
Social
50
Governance

People Also Bought